Novocure Limited · NASDAQ:NVCR
Novocure — Investor Presentation (July 2022)
45 slides from Novocure's investor presentation, July 2022
Slide 1: Novocure July 2022
novecure’ Novocure July 2022 patientforward”
Slide 2: Forward-looking statements
novocure forward-looking statements In addition to historical facts or statements of current condition, this presentation may contain forward-looking statements. Forward-looking statements provide Novocure's current expectations or forecasts of future events. These may include statements regarding a
Slide 3: Tumor Treating Fields
Tumor Treating Fields INTERRUPT MITOTIC DISRUPT CANCER INDUCE DEATH IN SPINDLE FORMATION CELL DIVISION AFFECTED CANCER CELLS Tumor Treating Fields are alternating electric fields tuned to specific frequencies to disrupt cancer cell division patien tforward © jovocure GmbH 3
Slide 4: Optune is intended as a treatment for adult patients with GBM
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
Slide 5: Approaching a critical inflection: platform modality
novecure’ 5 4 25,000+ FDA-APPROVED LATE-STAGE PATIENTS TREATED >20 yeals of INDICATIONS PHASE 3 TRIALS GLOBALLY , experlence IN 2 2022 GLOBAL COMMERCIAL BUSINESS IN 7 OF NET REVENUES THE WORLD'S LEADING MARKETS approaching a critical inflection platform modality ANTI-MITOTIC EFFECT OBSERVED IN EVERY
Slide 6: GBM business drives investments in innovation
GBM business drives investments in innovation net revenues (USD in millions) operating expenses (USD in millions ) ss ae | 1 5454 $133.5 1 ACTIVE PATIENTS ON THERAPY 80% GROSS MARGIN $949 CASH AS OF JUNE 30, 2022 $100 $100 $50 $50 so so MNorth America HEEMEA MiJapan ' Greater China MRSD MSSM GSA pat
Slide 7: A comprehensive strategy for long-term growth
novecure’ a comprehensive strategy for long-term growth , — , ~~ o ‘ a x / 4 = y / » t 5 3 \ ’ f \ \ ' PAB i , 7 “ARB 4 9. 0 Ry 4 —_) 80868 drive commercial advance deliver adoption clinical trials product innovation in approved in new indications to optimize indications and combinations TTFields th
Slide 8: Drive commercial adoption
novecure’ drive commercial adoption patientfo rward © 2022 Novocure GmbH 8
Slide 9: Glioblastoma: malignant brain cancer
novecure’ glioblastoma: malignant brain cancer WHO grade 4 15,000 cases diagnosed in the U.S. each yeart 49.1% of primary malignant brain tumors? 65: median age of newly diagnosed GBM patient2 14.6 to 16.7 months median overall survival® Early detection Is nearly 5-10% five-year survival rate imposs
Slide 10: Optune: proven to extend patient survival
novecure’ Optune: proven to extend patient survival EF-14 PHASE 3 PIVOTAL STUDY IN NEWLY DIAGNOSED GBM Overall survival (5-year survival analysis) na Hiticnonsin-2o9,andomssirinonts) —_%09__ 60 NEARLY HALF Log-rank P-value <0,001 ° f ea le vein —_ 087 HR (95% Cl) 0.63 (0.53-0.76) 43% 3 ee Re < o74 e
Slide 11: Optune: greater exposure increased survival
novecure’ Optune: greater exposure increased survival MEDIAN OVERALL SURVIVAL BY PERCENT OF TIME ON OPTUNE 25 months P-0.05 22 months P<005 gw Optune + TMZ , = TMZ al 20 months 005 “on OF PATIENTS RECEIVED A SURVIVAL JM te montnsao0s BENEFIT FROM OPTUNE BECAUSE se months THEY USED IT >50% OF THE TIM
Slide 12: Driving commercial growth in GBM
driving commercial growth in GBM strengthen HCP increase patient COMMERCIAL PENETRATION recommendation demand IN NEWLY DIAGNOSED GBM enter new geographic markets patient
Slide 13: Advance clinical trials
novecure’ advance clinical trials patientfo rward © 2022 Novocure GmbH 13
Slide 14: Expand label in approved indications
expand label in approved indications holistic strategy to \ expand | T Fields clinical footprint investigate use in new indications © 2022 Novocure GmbH 14 patient
Slide 15: Clinical pipeline by phase
PHASE 2 PHASE 3/4 APPROVED completed ✓
Slide 16: Multiple late-stage, randomized pivotal trials set to read out near-term
novecure’ multiple late-stage, randomized pivotal trials set to read out in near-term | ENROLLMENT COMPLETE ENROLLMENT COMPLETE | ENGOT-ov50/ z AN war OP Innovaris METIS @ panovas Ovarian Cancer + Evaluating TTFields with * Evaluating TTFields with * Evaluating TTFields after + Evaluating TTFields w
Slide 17: Substantial market expansion opportunity
substantial market expansion opportunity ANNUAL NUMBER OF U.S. PATIENTS* ~155,000 PATIENTS 43,000 l- —7—1 i] ! i] ! i] 38,000 I 1 I i] [ i] 16,000 ! 1 | 46,000 I I 35% I l penetrated ] in key markets u I 11,200 ! 1 I GBM NSCLC OVARIAN BRAIN METS PANCREATIC’ FUTURE I FROM NSCLC? I —<—=<4 patientforwa
Slide 18: Encouraging response rate in phase 2 gastric cancer trial
ocu encouraging response rate and durability signals in phase 2 gastric cancer trial EF-31 PHASE 2 PILOT TRIAL DESIGN? screening and baseline il ite i CT/MRI scan qQw survival evaluation (n=26) HER2+ pts) q3w until progression follow-up ql2w OBJECTIVE RESPONSE |} MEDIAN PROGRESSION- DURATION OF RATE
Slide 19: Ongoing research to identify optimal use
novecure’ ongoing research to identify optimal use --—— ANTI-MITOTIC IMPAIRS DNA REPAIR i Ss eee MECHANISMS OF ACTION OF TTFIELDS CELL MEMBRANE ._ PERMEABILITY AUTOPHAGY =. patientforward © 2022 Novocure GmbH 19 Rominiyi O, et al. Tumour treating fields therapy for glioblastoma: current advances and
Slide 20: TTFields plus immunotherapy translating to clinical results
novocure’ TTFields plus immunotherapy translating to clinical results eliciting immunogenic enhancing antitumor emerging signs of cell death efficacy clinical results Cell surface exposure of calreticulint In combination with anti-PD-1! 2-THE-TOP phase 2 interim clinical data? 9 rr of progression fr
Slide 21: KEYNOTE D58 builds upon promising 2-THE-TOP pilot data
novecure’ KEYNOTE D58 builds upon promising data from pilot 2-THE-TOP study N=26 patients Median PFS. N=26 patients Median OS oa 2-THE-TOP | 12.1 mos. 2 2-THE-TOP | 25.2 mos. = 9 EF-14 matched-control 7.9 mos. 2 Ll EF-14 matched-control 15.9 mos s = 2 (HR = 0.46; p=0.033) $ I (HR = 0.38; p=0.020) 8
Slide 22: Deliver product innovation
novecure’ deliver product Innovation patientfo rward © 2022 Novocure GmbH 22
Slide 23: Product roadmap to prioritize efficacy and ease of use
oc product roadmap to prioritize efficacy and ease of use field generator arrays software applications next gen device flex arrays MAXPOINT™ in development limited market release upcoming planning software high-intensity head array data generation EF-33 trial underway program underway patient © 2022
Slide 24: Greater intensity can lead to increased efficacy
novecure’ greater intensity can lead to increased efficacy Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical ‘Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial ie) FIELD TUMOR TREATING ae INTENSITY Se
Slide 25: Increased intensity led to greater cell death in vitro
novecure’ increased intensity led to greater cell death in vitro — vU373 B --- U87-MG glioma Z v= AI72 2 — _NCI-H520 lung ° Ey MSTO-241 mesothelioma 2 --- NCI-H2052 o o —_ KATO III ; $ astric FE “7 AGS 9 2 — _ OVCAR-3 : 3 --- Caov-3 ovarian “7 A2780 o : , , — HeLa : cervical 0.0 0.4 0.8 12 16 > Ca-S
Slide 26: Flex arrays designed for more efficient delivery
novecure’ flex arrays designed for more efficient delivery ARRAY PERFORMANCE Average Current (2-Channels) 2,250 FLEX ARRAY 2,000 -e—_a—reSeease a uF 1750 CURRENT ARRAY of 1,500 1.250 SP SPP PP PP PPP PF PSP 8 LPP. P PPP PPP PPP PPP PPP PL SP LSB PPP PS Time Lapsed (Hours) ory PAP AV APS AVERAGE AVER
Slide 27: Flex arrays increase coverage and dose
flex arrays Increase Coverage and dose I _no_background 10 V/cm | ; 10 cm 0 V/cm CURRENT ARRAYS FLEX ARRAYS AP channel, 1,588 mAmps AP channel, 1,988 mAmps patient © 2022 Novocure GmbH 27 Data on file. Simulation of electric field distribution in healthy brain model
Slide 28: Catalyst-rich through 2024
novecure’ catalyst-rich through 2024 2024 2021 2022 2023 2024 ANTICIPATED PIVOTAL DATA LUNAR phase 3 interim analysis LUNAR phase 3 enrollment complete INNOVATE phase 3 enrollment complete HEPANOVA-2 phase 2 data EF-31 gastric phase 2 enrollment complete patientforward INNOVATE-3 phase 3 interim ana
Slide 29: Together with our patients, we strive to extend survival
together with our patients, 4 we Strive to extend survival in some of the most aggressive forms of cancer patientforward
Slide 30: Appendix
novecure’ Appendix patientforward ; Contidertia
Slide 31: Increasing acceptance for TTFields across the global oncology community
novecure’ increasing acceptance for TTFields across the global oncology community @ Ourreach @ ISTs/inovivo/inovitro research © Offices @ Clinical development TUMOR TREATING FIELDS ECOSYSTEM patientforward ©2022 Novocure GmbH 31
Slide 32: Therapy is frequency-tuned to target dividing cancer cells
novecure’ therapy is frequency-tuned to target dividing cancer cells a TUMOR TREATING FIELDS 150 kHz 200 kHz Normal ntestine Intestin | | 50kHz 100 kHz 150 kHz 200 kHz 10 kHz 250 kHz Low Frequencies Intermediate High Frequencies DNA Damage cardiac defibrillator Frequencies radiofrequency ablation io
Slide 33: Ongoing LUNAR trial in non-small cell lung cancer
novecure’ ongoing LUNAR trial in non-small cell lung cancer LUNAR PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN? & ae mee CT q6wuntil dni [sels survival progression on screening 8 inhibitor/docetaxel progres follow-up visits (cliom-up or after platinum- fim baseline —— based therapy evaluatio
Slide 34: Ongoing INNOVATE-3 trial in ovarian cancer
novecure’ ongoing INNOVATE-S3 trial in ovarian cancer INNOVATE-3 PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! & TTFields + weekly [i CT/MRI scan q8w _ survival gernaore, s 7 paclitaxel until progressi follow-up a ae aS s weekly paclitaxel CT/MRI scan q8w [i survival S YP until progression f
Slide 35: Ongoing METIS trial in brain metastases
novecure’ ongoing METIS trial in brain metastases METIS PHASE 3 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! 6 Ee. Tumor Treating [i MRI q2m until ro 4 radiosurger Fields rogression screening and ji 8 a sey) pres baseline evaluation € 8 a _ MRI a2 til a] NY stereotactic a F An q2m unti g radiosurge
Slide 36: Ongoing PANOVA-3 trial in pancreatic cancer
novocure ongoing PANOVA-S trial in pancreatic C PANOVA-3 PHASE 3 PIV , OPEN-LABEL, RANDOMIZED TRIAL DESIGN* 5 el 7 CT g8w until post-PD survival screening and ic gemcitabine progression follow up visit follow-up q4w baseline fe evaluation 8 nab-paclitaxel + CT g8w until post-PD survival S gemcitabin
Slide 37: Ongoing TRIDENT trial in newly diagnosed GBM
novecure’ ongoing TRIDENT trial in newly diagnosed GBM TRIDENT PHASE 4 PIVOTAL, OPEN-LABEL, RANDOMIZED TRIAL DESIGN! TTFields + RT TTFields + MRI q8w until + TMZ maintenance TMZ progression survival follow-up screening and baseline evaluation TTFields + MRI q8w until survival Ba spb, maintenance TMZ
Slide 38: Ongoing KEYNOTE B36 trial in non-small cell lung cancer
novecure’ ongoing KEYNOTE B36 trial in non-small cell lung cancer KEYNOTE B36 PHASE 2 PILOT TRIAL DESIGN* screening and TTFields (150 kHz) CT/MRI scan q9w until post-progression survival baseline evaluation JJ + pembrolizumab progression or 24 mo follow-up follow-up @ KEYNOTE B36 Lung Cancer STUDY D
Slide 39: Enrollment ongoing to test new high-intensity array concept in EF-33
novecure’ enrollment ongoing to test new high-intensity array concept in EF-535 clinical trial PRECLINICAL RATIONALE PHASE 2 PILOT TRIAL DESIGN TESTING SAFETY AND EFFICACY OF TTFIELDS DELIVERED THROUGH HIGH-INTENSITY ARRAYS IN RECURRENT GBM? STANDARD 9-DISC HIGH-INTENSITY 14-DISC TRANSDUCER ARRAYS T
Slide 40: Growing evidence supports broad applicability in combination therapies
novecure’ growing evidence supports broad applicability in combination with certain other cancer therapies TUMOR TREATING FIEL WITH RADIATION THERAPY: WITH CERTAIN WITH CERTAIN CHEMOTHERAPIES2 IMMUNOTHERAPIES> - . 300 100 ” 150: — Paclitaxel 3 = 90 2 —s- Paclitaxel + TTFields © aon $ 80 as e = 70 ££
Slide 41: Kaplan-Meier OS
Kaplan-Meier OS Kaplan-Meier OS
Slide 42: TTFields can elicit immunogenic cell death
novecure’ TTFields can elicit immunogenic cell death through induction of various forms of stress in vitro Triggers apoptosis followed by extracellular release of HMGB1! May mediate cell surface Induces autophagy dependent exposure of calreticulin! reduction in intracellular ATP levels! g $s 8 8 N S
Slide 43: In vivo data suggest TTFields with anti-PD-1 increased tumor control
novecure’ in vivo data suggest TTFields together with anti-PD-1 therapy resulted in increased tumor control Lewis lung carcinoma S00 TTFields r ——1 ; 520 — _ a-PD-1 (250y1g/mouse, i.p.) z LLC; Orthotopic | ! | 3 100 | ! ! e 0 6 7 10 13 15 Q g Ss Days after tumor inoculation — we « ae 3 & og murine c
Slide 44: Optune Lua and Optune indications for use and important safety information
novecure’ Optune Lua™ and Optune® indications for use and important safety information INDICATIONS Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of a
Slide 45: Warnings and precautions
novecure’ Optune Lua™ and Optune® indications for use and important safety information WARNINGS AND PRECAUTIONS » Optune and Optune Lua can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure®. * The most common (210%) adverse event